Rheumatology billing is mostly drug billing with an office visit attached. A practice running an infusion suite buys infliximab, rituximab or abatacept up front, bills the J-code with the right units, adds the administration codes, and waits. If the drug units are off by one vial, or the wasted portion is missing its JW or JZ modifier, the claim pays short or not at all, and nobody notices for ninety days. The visit side has its own traps: a modifier 25 on the E/M when a joint injection happened the same day, ultrasound guidance that gets bundled into the injection code, and bone density and musculoskeletal ultrasound that need a diagnosis the payer actually accepts.
Prior authorization is where the real work sits. Biologics get authorized by drug, dose and interval, and plans re-authorize on their own calendar. Step therapy rules change the preferred product, so a patient stable on one biologic can be told to switch to a biosimilar mid-year. Some plans insist on specialty pharmacy supply, which means white-bagging, which means the drug shows up with someone else's name on it and you bill only the administration. In-house staff tend to treat each of these as a one-time task. It is a standing queue, and when it slips, chairs go empty and drug sits on a shelf you have already paid for.
Medicare Part B drugs, commercial plans, and Medicare Advantage each behave differently, and hospital outpatient infusion centers compete with you on the same patients. A good rheumatology biller watches payment per drug against what you paid for it, tracks denials by drug and by payer, and works the copay assistance paperwork that keeps patients on therapy. Outsourcing makes sense when the infusion volume has outgrown one person's attention, or when your authorization specialist is also your front desk. It makes less sense for a two-physician office with no infusions and a small, clean AR. Use the form to say whether you infuse, how many chairs you run, and which payers hold most of your receivables.
